Maravai LifeSciences stock gets a TD Cowen strong buy rating

Published on 10/07/2026 at 01:19 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

TD Cowen set a USD 9.00 target on October 5, 2026, while MarketBeat reported a strong-buy upgrade the next day. Q2 revenue reached USD 51.44 million.

MRVI, US56600D1072, Illustration mit AI erstellt.

Maravai LifeSciences stock (ISIN US56600D1072) received a strong-buy upgrade reported on October 6, 2026, with the latest analyst target at USD 9.00. The rating change puts renewed attention on whether CleanCap growth can convert into durable earnings.

Analyst targets split the view

According to MarketBeat on October 6, 2026, TD Cowen upgraded Maravai to a strong-buy rating. The same report listed one strong buy, two buys, one hold and one sell among five analysts, producing a Moderate Buy consensus and an average target of USD 7.38.

Investing.com reported on October 5, 2026, that TD Cowen initiated coverage with a buy rating and a USD 9.00 price target. At the USD 7.90 reference price cited in that report, the target stood 13.9 percent above the price.

Q2 revenue beat expectations

Maravai's latest reported quarter ended June 30, 2026. The company generated USD 51.44 million in revenue, exceeding the USD 48.67 million consensus estimate, while its adjusted loss of USD 0.02 per share was better than the expected USD 0.04 loss, according to MarketBeat.

The earnings improvement also reached adjusted profitability. Yahoo Finance reported that Q2 adjusted EBITDA was USD 8.7 million, up from a negative USD 10.4 million in the year-earlier quarter. Management also raised full-year adjusted EBITDA guidance to USD 33 million to USD 35 million from USD 30 million to USD 32 million, while retaining revenue guidance of USD 205 million to USD 215 million.

The operational story centers on TriLink BioTechnologies and its CleanCap nucleic acid technology. Maravai says its portfolio serves vaccine, therapeutic and diagnostic development through nucleic acids, enzymes and bioprocess impurity testing, as described on its Maravai LifeSciences investor page.

Market value and yearly range

Maravai LifeSciences had a market capitalization of USD 2.2 billion on October 6, 2026. Its 52-week range was USD 2.55 to USD 9.42, leaving the analyst targets dependent on continued operating improvement rather than a settled profit record.